Disease-Modifying Alzheimer's Drugs: Current State and Limitations
No currently available Alzheimer's drug can reverse the disease—lecanemab (Leqembi) and similar anti-amyloid monoclonal antibodies can only modestly slow cognitive decline in early-stage disease, not reverse existing damage. 1
What These Drugs Actually Do
Disease-modifying therapies target underlying pathology but do not cure or reverse Alzheimer's disease. The FDA-approved anti-amyloid monoclonal antibodies—lecanemab, donanemab, and previously aducanumab—are designed to reduce amyloid plaque burden in the brain, representing the first treatments expected to provide disease-modifying therapy rather than purely symptomatic relief. 2
Lecanemab (Leqembi) Specifics
Indication: Treatment of Alzheimer's disease in patients with mild cognitive impairment or mild dementia stage (early AD) with confirmed amyloid pathology. 1
Mechanism: Humanized IgG1 monoclonal antibody that binds with high affinity to amyloid-beta soluble protofibrils, reducing brain amyloid burden by approximately 59 centiloids compared to placebo. 3
Clinical Effect: At 18 months, lecanemab slowed cognitive decline by approximately 27-30% compared to placebo on the CDR-SB scale (difference of -0.45 points), with continued benefit through 36 months. 4, 3, 5 This represents slowing of decline, not improvement or reversal—patients still worsen, just at a slower rate.
Dosing: 10 mg/kg intravenously every 2 weeks for 18 months, with option to continue every 2 weeks or transition to every 4 weeks maintenance dosing thereafter. 1
Critical Safety Concerns
Amyloid-Related Imaging Abnormalities (ARIA)
ARIA represents the most serious safety concern and can be fatal. 1
ARIA-E (edema/effusion): Occurred in 12.6% of lecanemab-treated patients, usually early in treatment (first 14 weeks). 1, 3
ARIA-H (hemorrhage): Includes microhemorrhages and serious intracerebral hemorrhages >1 cm, some fatal. 1
ApoE ε4 homozygotes (approximately 15% of AD patients) have substantially higher risk of symptomatic, serious, and severe ARIA compared to heterozygotes and non-carriers. Genetic testing for ApoE ε4 status must be performed before initiating treatment. 1, 6
Monitoring requirements: Baseline brain MRI before treatment, then MRI before the 5th, 7th, and 14th infusions, with specific dosing interruption protocols based on ARIA severity. 1
Other Adverse Events
Infusion-related reactions: Occurred in 26.4% of patients in clinical trials and 16.5% in real-world Chinese cohort. 3, 7
Brain volume loss: Observed but poorly understood phenomenon requiring further investigation. 5
Who Cannot Receive These Drugs
Lecanemab is contraindicated in patients with serious hypersensitivity to lecanemab or its excipients. 1
Treatment should not be initiated in patients with:
- Moderate to severe dementia (only early AD: MCI or mild dementia). 1
- Absence of confirmed amyloid pathology (requires PET, CSF, or blood biomarker confirmation). 8, 1
- Severe baseline ARIA on MRI. 1
- Active anticoagulation with increased bleeding risk. 6
The Reality of "Disease Modification"
These drugs slow progression but do not stop, reverse, or cure Alzheimer's disease. 2, 9 All types of dementia, including AD, remain progressive and will lead to more severe cognitive and physical impairment over time with increasing dependency on caregivers. 9
The approximately 30% slowing of decline is considered "moderately less decline" and "clinically meaningful" in terms of extended cognitive integrity and delayed onset of severe dementia phases, but patients continue to deteriorate. 3, 5 The clinical significance remains debated—NICE in the UK declined to recommend lecanemab due to concerns about whether efficacy outcomes translate into clinically meaningful improvement given treatment costs and risks. 10
Practical Implementation Challenges
Limited specialist availability: Too few dementia specialists to handle expected patient volume, with projected 18.6-month wait times for treatment. 11
Diagnostic requirements: Biomarker confirmation of amyloid pathology required, necessitating expensive PET imaging (approximately $8,000 per screening), CSF testing, or emerging blood biomarkers. 2, 8
Resource intensity: Treatment requires comprehensive multidisciplinary teams, regular MRI monitoring, infusion facilities, and management of ARIA complications. 6
Healthcare system strain: Current systems, including the NHS, face resource constraints that challenge implementation of these therapies. 10
Comparison to Symptomatic Treatments
Traditional AD medications (donepezil, rivastigmine, galantamine, memantine) are palliative treatments that temporarily reduce symptoms but do not prevent or slow disease progression. 2, 9 Anti-amyloid antibodies represent the first class expected to modify disease course, but the distinction is one of degree—slowing rather than stopping or reversing pathology.